G6PD deficiency-does it alter the course of COVID-19 infections?
Tsz Yuen AuOskar Wojciech WiśniewskiShamiram BenjaminTadeusz KubickiDominik DytfeldLidia GilPublished in: Annals of hematology (2023)
Despite the existence of well-founded data around the relationship between reactive oxygen species (ROS) and glucose-6-phosphate dehydrogenase (G6PD), current research around G6PD-deficient patients with viral infections, and limitations as a result of their condition, are inadequate. Here, we analyze existing data around immunological risks, complications, and consequences of this disease, particularly in relation to COVID-19 infections and treatment. The relationship between G6PD deficiency and elevated ROS leading to increased viral load suggests that these patients may confer heightened infectivity. Additionally, worsened prognoses and more severe complications of infection may be realized in class I G6PD-deficient individuals. Though more research is demanded on the topic, preliminary studies suggest that antioxidative therapy which reduces ROS levels in these patients could prove beneficial in the treatment of viral infections in G6PD-deficient individuals.
Keyphrases
- reactive oxygen species
- sars cov
- end stage renal disease
- coronavirus disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- dna damage
- prognostic factors
- risk factors
- blood pressure
- type diabetes
- mesenchymal stem cells
- patient reported outcomes
- big data
- bone marrow
- climate change
- oxidative stress
- skeletal muscle
- risk assessment
- anti inflammatory
- cell therapy
- wild type
- smoking cessation
- drug induced
- data analysis